FDA MicroBalance coverage for business development, investment, and market access teams
The FDA has approved MicroBalance, a novel microbiome therapy designed to treat Crohn's Disease, marking a significant advancement in patient care.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
